Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Gribbon

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Expert Opinion on Drug Discovery|July 25, 2012
Exemplification of the challenges associated with utilising fluorescence intensity based assays in discoverySheraz Gul, Philip Gribbon
Expert Opinion on Drug Discovery|February 20, 2016
Risk mitigation in academic drug discoveryBernhard Ellinger, Philip Gribbon
Drug Discovery Today|December 24, 2003
Fluorescence readouts in HTS: no gain without pain?Philip Gribbon, Andreas Sewing
Drugs|March 7, 2022
Drug Repurposing to Target Neuroinflammation and Sensory Neuron-Dependent PainMarco Sisignano, Philip Gribbon, Gerd Geisslinger
ACS Omega|August 28, 2023
Pharmacophore-Based Machine Learning Model To Predict Ligand Selectivity for E3 Ligase BindersReagon Karki, Yojana Gadiya, Philip Gribbon, et al.
Bioinformatics Advances|May 15, 2023
Mpox Knowledge Graph: a comprehensive representation embedding chemical entities and associated biology of MpoxReagon Karki, Yojana Gadiya, Andrea Zaliani, et al.
Journal of Biomolecular Screening|September 1, 2006
The application of fluorescence lifetime readouts in high-throughput screeningJulian Moger, Philip Gribbon, Andreas Sewing, et al.
Archives of Toxicology|February 28, 2009
Induced pluripotent stem cells: a new tool for toxicology screening?Boon Chin Heng, Mark Richards, Yimin Shu, et al.
Bioinformatics (Oxford, England)|November 2, 2022
PEMT: a patent enrichment tool for drug discoveryYojana Gadiya, Andrea Zaliani, Philip Gribbon, et al.
Nature Reviews. Drug Discovery|November 21, 2015
Towards a hit for every targetSteve Rees, Philip Gribbon, Karen Birmingham, et al.
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Expert Opinion on Drug Discovery|July 25, 2012
Exemplification of the challenges associated with utilising fluorescence intensity based assays in discoverySheraz Gul, Philip Gribbon
Expert Opinion on Drug Discovery|February 20, 2016
Risk mitigation in academic drug discoveryBernhard Ellinger, Philip Gribbon
Drug Discovery Today|December 24, 2003
Fluorescence readouts in HTS: no gain without pain?Philip Gribbon, Andreas Sewing
Drugs|March 7, 2022
Drug Repurposing to Target Neuroinflammation and Sensory Neuron-Dependent PainMarco Sisignano, Philip Gribbon, Gerd Geisslinger
ACS Omega|August 28, 2023
Pharmacophore-Based Machine Learning Model To Predict Ligand Selectivity for E3 Ligase BindersReagon Karki, Yojana Gadiya, Philip Gribbon, et al.
Bioinformatics Advances|May 15, 2023
Mpox Knowledge Graph: a comprehensive representation embedding chemical entities and associated biology of MpoxReagon Karki, Yojana Gadiya, Andrea Zaliani, et al.
Journal of Biomolecular Screening|September 1, 2006
The application of fluorescence lifetime readouts in high-throughput screeningJulian Moger, Philip Gribbon, Andreas Sewing, et al.
Archives of Toxicology|February 28, 2009
Induced pluripotent stem cells: a new tool for toxicology screening?Boon Chin Heng, Mark Richards, Yimin Shu, et al.
Bioinformatics (Oxford, England)|November 2, 2022
PEMT: a patent enrichment tool for drug discoveryYojana Gadiya, Andrea Zaliani, Philip Gribbon, et al.
Nature Reviews. Drug Discovery|November 21, 2015
Towards a hit for every targetSteve Rees, Philip Gribbon, Karen Birmingham, et al.
Pageof 9